European access and reimbursement
Market Access Checklist & Free Consultation
Access preparedness starts now
In today’s turbulent geopolitical dynamics, there are many more moving parts when it comes to pricing, reimbursement and market access. Strategic access and price considerations are getting more complex and need to be taken earlier in development. Fund raising, partnering and licensing deals are harder to come by, favouring the best prepared companies. While several US policies now aim to push a US-centric development and first-time launch, side-lining European and global markets and their potential revenues is not going to be a viable business model for many companies.
Creating a valuable global asset today means staying on top of dynamic policy developments, to evaluate policy impact and incorporate new realities and scenarios instead of standing still, immobilised by market uncertainty. Questions of strategic positioning, patient need, launch and pricing need to be aligned with clinical and regulatory efforts to create opportunities in the tension between global and local.
Putting in place early activities to proactively follow and evaluate policies and competitor efforts, to understand opportunities more broadly than a list price will be the way forward in European and international Market Access as we are going through 2026. Coherent global Market Access Excellence will help to navigate conflicting international priorities strategically.
Get a head-start for European payer requirements & market access
Checklist
Download the checklist below and use it as a guide. Tick the boxes and note your organisation’s familiarity with each domain or question.
Priorities
Identify your current priorities and needs in terms of Market Access knowledge. This might be your value story, a validation of first price assumptions for investors or the preparation of a new trial protocol …
Free Consultation
We will discuss each item on the checklist, identify gaps and risks, and validate priorities. – The goal is to provide you with actionable next steps to bring your access readiness to the right level for your asset at this point of development.
European Market Access Checklist download
Enter your details to obtain the checklist file.
This checklist, derived from specialist knowledge of the European Health Technology Assessment (HTA) systems and pricing environments, is designed to help biotechs – typically in Phase 1-2 – to identify and close critical strategic knowledge gaps and related evidence gaps that can cause costly delays and suboptimal reimbursement.
Free Consultation
45 minutes discussion
After the Checklist download, we will contact you regarding a free consultation. Alternatively, book a call here already.
During the consultation call, se will discuss each item on the checklist, identify gaps and risks, and validate priorities. The goal is to assess your situation, answer questions and help you plan actionable next steps to progress your access readiness for Europe and in a global strategy context.